Cargando…

Genetic tracing of HCoV-19 for the re-emerging outbreak of COVID-19 in Beijing, China

Detalles Bibliográficos
Autores principales:	Yang, Jing, Niu, Peihua, Chen, Lijuan, Wang, Liang, Zhao, Li, Huang, Baoying, Ma, Juncai, Hu, Songnian, Wu, Linhuan, Wu, Guizhen, Huang, Chun, Bi, Yuhai, Tan, Wenjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Higher Education Press 2020
Materias:	Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430935/ https://www.ncbi.nlm.nih.gov/pubmed/32808156 http://dx.doi.org/10.1007/s13238-020-00772-0

Ejemplares similares

Human Coronaviruses HCoV-NL63 and HCoV-HKU1 in Hospitalized Children with Acute Respiratory Infections in Beijing, China
por: Cui, Li-Jin, et al.
Publicado: (2011)

Coronavirus humains (HCoV)
por: Vabret, A., et al.
Publicado: (2009)

Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host
por: Forni, Diego, et al.
Publicado: (2021)

Titration of Human Coronaviruses, HCoV-229E and HCoV-OC43, by an Indirect Immunoperoxidase Assay
por: Lambert, Francine, et al.
Publicado: (2007)

Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice
por: Niu, Junwei, et al.
Publicado: (2020)

Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry
por: Sun, Huan, et al.
Publicado: (2020)

Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study
por: Aldridge, Robert W., et al.
Publicado: (2020)

Heparan Sulfate and Enoxaparin Interact at the Interface of the Spike Protein of HCoV-229E but Not with HCoV-OC43
por: Fuochi, Virginia, et al.
Publicado: (2023)

Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2
por: Liu, Donglan, et al.
Publicado: (2023)

Seroconversion to HCoV-NL63 in Rhesus Macaques
por: Dijkman, Ronald, et al.
Publicado: (2009)

Understanding Human Coronavirus HCoV-NL63
por: Abdul-Rasool, Sahar, et al.
Publicado: (2010)

Novel polymeric inhibitors of HCoV-NL63
por: Milewska, Aleksandra, et al.
Publicado: (2013)

HCoV-229E Infects and Activates Monocytes
por: Desforges, Marc, et al.
Publicado: (2006)

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2012)

Structural characterization of the HCoV-229E fusion core
por: Zhang, Wei, et al.
Publicado: (2018)

Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1)
por: Dugas, Martin, et al.
Publicado: (2021)

Baculovirus expression of HCoV-OC43 nucleocapsid protein and development of a Western blot assay for detection of human antibodies against HCoV-OC43
por: Mourez, Thomas, et al.
Publicado: (2007)

HCoV-Oc43–Induced Apoptosis of Murine Neuronal Cells
por: Jacomy, Hélène, et al.
Publicado: (2006)

HCoV-OC43–Induced Encephalitis is in Part Immune-Mediated
por: Butler, Noah, et al.
Publicado: (2006)

Epidemiology of respiratory coronaviruses (HCoV) in a Dutch university hospital
por: Niesters, H.G.M., et al.
Publicado: (2006)

Zoonotic origins of human coronavirus 2019 (HCoV-19 / SARS-CoV-2): why is this work important?
por: Wong, Gary, et al.
Publicado: (2020)

Improving human coronavirus OC43 (HCoV-OC43) research comparability in studies using HCoV-OC43 as a surrogate for SARS-CoV-2
por: Schirtzinger, Erin E., et al.
Publicado: (2022)

Pan-Coronavirus CRISPR-CasRx Effector System Significantly Reduces Viable Titer in HCoV-OC43, HCoV-229E, and SARS-CoV-2
por: Mayes, Cathryn M., et al.
Publicado: (2023)

Artificial Light at Night (ALAN): A Potential Anthropogenic Component for the COVID-19 and HCoVs Outbreak
por: Khan, Zeeshan Ahmad, et al.
Publicado: (2020)

The human coronavirus HCoV-229E S-protein structure and receptor binding
por: Li, Zhijie, et al.
Publicado: (2019)

Inhibition of HCoV-NL63 infection at early stages of the replication cycle
por: van der Hoek, L., et al.
Publicado: (2006)

Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia
por: Lynch, Sean A., et al.
Publicado: (2021)

Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator
por: Chen, Yongkang, et al.
Publicado: (2022)

Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein
por: Xiang, Jiangchao, et al.
Publicado: (2022)

SNAP@CQD as a promising therapeutic vehicle against HCoVs: An overview
por: Chatterjee, Satyaki, et al.
Publicado: (2023)

Human Milk Antibodies against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with a Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers
por: Demers-Mathieu, Veronique, et al.
Publicado: (2021)

HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients
por: Steiner, Sophie, et al.
Publicado: (2020)

The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection
por: Santacroce, Luigi, et al.
Publicado: (2020)

Origins of HIV, HCoV-HKU1, SFTSV, and MERS-CoV and Beyond
por: Liu, Wenli, et al.
Publicado: (2022)

Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex
por: Feng, Yongmei, et al.
Publicado: (2022)

Inhibition by components of Glycyrrhiza uralensis of 3CLpro and HCoV-OC43 proliferation
por: Kim, Jang Hoon, et al.
Publicado: (2023)

SARS-CoV, But not HCoV-NL63, Utilizes Cathepsins to Infect Cells: Viral Entry
por: Huang, I-Chueh, et al.
Publicado: (2006)

Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

Corrigendum to ’Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506’ Virus Research (2012) 165/1 [112-117]: Corrigendum
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2022)

Reemergent Cases of COVID-19 — Xinfadi Wholesales Market, Beijing Municipality, China, June 11, 2020
por: Tan, Wenjie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tvc1s0t4d4fpq0eo407n7i1djb